Get the Stockscreener App
56.83
0.14%
0.08
After Hours:
56.83
Janux Therapeutics Inc stock is traded at $56.83, with a volume of 1.10M.
It is up +0.14% in the last 24 hours and up +16.07% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
See More
Previous Close:
$56.75
Open:
$56.37
24h Volume:
1.10M
Relative Volume:
1.16
Market Cap:
$3.33B
Revenue:
$13.05M
Net Income/Loss:
$-60.54M
P/E Ratio:
-34.87
EPS:
-1.63
Net Cash Flow:
$-37.82M
1W Performance:
-7.00%
1M Performance:
+16.07%
6M Performance:
+41.02%
1Y Performance:
+496.33%
1-Day Range:
$55.63
$59.72
1-Week Range:
$54.20
$63.00
52-Week Range:
$7.79
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
56.83 | 3.33B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Wellington Management Group LLP Sells 29,436 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of "Buy" from Analysts - MarketBeat
State Street Corp Sells 40,056 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Barclays PLC - MarketBeat
Finance Watch: FOPO Surge Continues With Big Offerings From Revolution, NewAmsterdam - Scrip
How to Take Advantage of moves in (JANX) - Stock Traders Daily
Janux Nets $350M in Stock Sale - San Diego Business Journal
Neo Ivy Capital Management Buys Shares of 20,674 Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Navigating 10 Analyst Ratings For Janux Therapeutics - Benzinga
Charles Schwab Investment Management Inc. Raises Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Polar Asset Management Partners Inc. Buys New Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Point72 Asset Management L.P. Boosts Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics Raises Massive $402.5M in Oversubscribed Public Offering - StockTitan
Revolution , Janux prep for next steps with follow-on cash - BioCentury
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million - Business Wire
Wilson Sonsini Advises Janux Therapeutics on Patent Matters Related to $350 Million Underwritten Public Offering - Wilson Sonsini
Janux, Vir stocks rally on positive data for Janux drug JANX007 - MSN
Janux Therapeutics prices $350M securities offering - MSN
Readystate Asset Management LP Acquires New Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Latham Advises on Janux Therapeutics’ US$350 Million Public Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP
JANX Stock Hits Record High on Prostate Cancer Study Data - MSN
Samsara BioCapital LLC Sells 22,526 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance
Janux Therapeutics, Inc. (NASDAQ:JANX) Stake Boosted by Janus Henderson Group PLC - MarketBeat
Janux Therapeutics Launches Massive $350M Public Offering to Fuel Clinical Pipeline Growth - StockTitan
Why Janux Therapeutics Crushed the Market Today - MSN
Janux Therapeutics Stock Hits 7-Month High On Prostate Cancer Drug Trial Data: Retail Confidence Spikes - MSN
Scotiabank lifts Janux Therapeutics shares target on strong position By Investing.com - Investing.com Canada
AstraZeneca’s new EVP of international amid China investigation; Janux’s $300M offering - Endpoints News
Janux Has A License To Thrill With 007’s Prostate Cancer Results - News & Insights
Janux Therapeutics CEO sells $1 million in stock By Investing.com - Investing.com Canada
Cartesian Therapeutics Reports Promising Phase 2b Trial Results - Yahoo Finance
Insider Sell: David Campbell Sells 15,000 Shares of Janux Therap - GuruFocus.com
Janux Therapeutics CEO sells $1 million in stock - Investing.com
Confidence in masked T cell engagers builds with Janux update - BioCentury
Janux Therapeutics share target lifted, buy rating held on strong trial data - Investing.com Canada
Health Care Down, But Near All-Time Highs, as Biotech Firms Gain -- Health Care Roundup - Marketscreener.com
Janux Therapeutics soars on clinical trial data for prostate cancer treatment candidate - Mugglehead
Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride - Yahoo! Voices
Biotech Rockets 49% To Record High On 'Unprecedented' Results - Investor's Business Daily
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine - Yahoo Finance
Janux Therapeutics Announces Proposed Public Offering - Business Wire
Janux's T-cell engager data sparks buzz about possible Pluvicto challenger - FirstWord Pharma
Janux updates clinical results for JANX007, stock rated Outperform as sales estimate rises to $3B - Investing.com
Janux Therapeutics stock positioned for growth, Stifel raises PT with Buy rating - Investing.com
Janux Rockets 41% in Five Days as Cancer Breakthrough Fuels Market Buzz - Yahoo Finance
Leerink boosts Janux Therapeutics shares target on trial data By Investing.com - Investing.com Nigeria
Janux's T-cell engager makes waves, again, with 'best-in-class' data drop: analyst - Fierce Biotech
Janux Therapeutics stock holds Buy rating, analyst sees potential By Investing.com - Investing.com Nigeria
Janux Therapeutics Stock Soars 63% on Prostate Cancer Drug Trial Results - Barron's
Janux impresses Wall Street with new prostate cancer drug results - BioPharma Dive
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Janux Therapeutics Inc Stock (JANX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Campbell David Alan | President and CEO |
Dec 03 '24 |
Sale |
67.00 |
15,000 |
1,005,000 |
242,054 |
| Campbell David Alan | President and CEO |
Nov 25 '24 |
Sale |
51.60 |
25,000 |
1,289,879 |
257,054 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):